Purpose: To critically appraise scientific evidence regarding the efficacy of nutritional supplementation with omega-3 and omega-6 fatty acids for the treatment of dry eye syndrome (DES). Methods: A systematic review of randomized clinical trials was performed. Two independent reviewers selected and analysed the scientific papers that met inclusion and exclusion criteria. Objective and subjective efficacy outcomes were assessed. Results: The trials involved a total of 2591 patients in fifteen independent studies. All studies were published between 2005 and 2015. The supplements used were mostly omega-3 and omega-6 in different proportions. Subjective improvement was measured using mainly Ocular Surface Disease Index (OSDI) test and Dry Eye Severity Score (DESS) test: significant differences in favour of the experimental group were found in seven of the studies. The objective amelioration was assessed by lacrimal function parameters: Tear break-up time (TBUT) significantly increased in nine studies and Schirmer's test in four studies. Conclusion: We observed a discrete improvement in the parameters of tear function. Scientific evidence is not strong enough to systematically recommend the use of omega-3 and omega-6 fatty acids as a standalone treatment of DES independently from its aetiology. However, they could be considered as an effective alternative to topical treatment in patients with DES secondary to certain pathologies.
Introduction
Dry eye syndrome (DES) is a common pathology with an estimated prevalence of 10-30% of the population (Vehof et al. 2014; Li et al. 2015) . Classically, DES was linked to ageing, but with modern lifestyles which include the intensive use of backlit screens such as computer displays or smartphones, the use of contact lenses and corneal refractive surgery, its incidence among young subjects has increased (Ong et al. 2013; Ahn et al. 2014; Tauste et al. 2014 ). The most common symptoms of DES are eye redness, dryness, gritty sensation, burning, pain, ocular fatigue and blurry vision. These produce a significant impairment of quality of life (Paulsen et al. 2014) .
Typically, the therapeutic approach of DES is based on topical measures. The instillation of artificial teardrops is the most frequently used treatment. However, patients do not always accept and comply with topical treatment. Some refuse to self-apply topical measures to their eyes, while others feel uncomfortable instilling eye drops several times a day.
In recent years, an increasing number of nutritional supplements containing omega-3 and omega-6 fatty acids aiming to improve DES symptoms have been developed. Essential fatty acids are necessary to maintain good health and cannot be synthesized by human beings. The most important polyunsaturated fatty acids are omega-3 (n-3 PUFA) and omega-6 (n-6 PUFA), which play an important role in regulating the inflammatory and immune response.
Arachidonic acid (AA) is an n-6 metabolite and the precursor of prostaglandins, leukotrienes and other immune molecules. The n-3 PUFA metabolites, docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), compete with AA to incorporate in cellular membrane phospholipids (Calder & Grimble 2002) . Fish oil contains the n-3 PUFA EPA. The increment of fatty fish consumption results in partial replacement of AA in cell membranes by EPA. This leads to decreased production of AA-derived mediators. In addition, EPA is a substrate for cyclooxygenase and lipoxygenase and gives rise to mediators that often have different biological actions or potencies than those formed from AA. Animal studies have reported higher levels of n-3 PUFAs in retina and lacrimal system achieving lower local inflammation (Simon et al. 2011; Andrade et al. 2014) . The balance between these two PUFAs can result in an anti-inflammatory or a proinflammatory status in the organism.
In Western countries, the ratio omega-3:omega-6 is approximately 1:15 favouring a pro-inflammatory status, which could benefit from the oral supplementation of omega-3 and omega-6 fatty acids. Fatty fish is the main source of EPA and DHA. alinolenic acid (ALA) is found in flaxseed oil (flaxseed oil has the highest linolenic content of any food) and other seeds oil and vegetables. Patients with rheumatoid arthritis or coronary heart disease have experienced positive results with oral supplementation of omega-3 and omega-6 fatty acids (Kremer 2000; Huth et al. 2015) . The pathogenesis of DES includes the presence of inflammatory cytokines such as IL-6, IL-8, IL-12, TNF-a e IFN-c on the ocular surface triggered by the dryness that would change the tear film osmolarity producing more inflammation and perpetuating the phenomenon in a positive feedback process (Tsubota et al. 1999; Rolando et al. 2005; Lam et al. 2009; Brignole-Baudouin et al. 2011) .
Nowadays, DES is interpreted as chronic inflammation in ocular surface that starts with tear hyperosmolarity and promotes ocular changes increasing dry eye symptoms and severity (Luo et al. 2005 ). According to these findings, oral supplementation with omega-3 and omega-6 fatty acids could improve inflammation on the ocular surface and relieve symptoms of DES (Jackson et al. 2011) . Given this new therapeutic alternative, we pose a question: should I include it in my routine clinical practice?
The aim of this systematic review is to critically appraise scientific evidence regarding the efficacy of nutritional supplementation with omega-3 and omega-6 fatty acids for the treatment of DES.
Materials and Methods

Electronic search
On 15 September 2015, we performed a bibliographic search in the following electronic databases: PubMed, Scopus, TripDatabase, Cochrane Central Register of Controlled Trials (CENTRAL) and Web of Science. Key words were: "dry eye" OR "dry eye syndromes" OR "keratoconjunctivitis sicca" combined with "diet" "supplement" "omega fatty acid" and "PUFA".
Search limits were publication date in the last 10 years, location of the search terms in title, abstract or keywords. There were language restrictions in two studies (Chinese and German). We considered the references of the articles extracted to find further relevant publications.
Selection criteria
(1) Study design: randomized controlled trials (RCTs) (2) Participant characteristics: subjects suffering DES of any aetiology diagnosed using validated objective or subjective criteria. 
Data extraction
Two independent reviewers selected and analysed the scientific papers that met inclusion and exclusion criteria.
From each study, the following information was extracted: first author, year of publication, journal, type of study, dry eye severity and aetiology, sample size, study population characteristics type of supplement, duration of tracking, symptoms scale results, TBUT and Schirmer's test results.
In studies with several groups of intervention, the treatment group with the highest dose of oral supplementation would be analysed against placebo.
Main variables of interest
Subjective amelioration: expressed by the use of some questionnaires. We could divide these into OSDI, DESS and others. The first two are validated questionnaires that extrapolate the frequency of dry eye symptoms to a severity of DES. The questionnaires tagged as 'others' also evaluate different symptoms, but they are all different to each other, making them incomparable.
Objective improvement using two variables of tear function: TBUT, which measures lacrimal film stability, and Schirmer's test, which evaluates the amount of tears produced. This test could be performed with anaesthesia, Schirmer type 2, or without anaesthesia, Schirmer type 1.
Quality evaluation
The Cochrane Collaboration Tool is used to assess the quality of each study and the risk of bias (Higgins & Green 2011) .
Results
Search results
The 15 studies selected after applying inclusion and exclusion criteria are shown in the flow chart (Fig. 1) . These studies involved a total of 2591 patients.
Sociodemographic features
Regarding participants age, the median was 52.2 years old (SD 14.6), with a bimodal distribution. There was one peak at 34.34 years old (IQR 16.06 ) and another at 59.03 years old (IQR 1.79). There were no differences in age between experimental and control groups.
Regarding gender distribution, there was a predominance of female participants with female/male odds of 3 (Table 1) .
Dry eye aetiology
The list of studies according to DES aetiology is shown in Table 1 .
Contact lens wearers
Two studies analyse the effect of oral supplementation in patients suffering dry eye because of the use of soft contact lens. Bhargava & Kumar (2015) used a combination of omega-3 fatty acids (EPA + DHA) in close to 600 patients finding a significant improvement in signs and symptoms. In contrast, Kokke et al. did not obtain significant differences in TBUT or Schirmer's test employing an omega-6 supplement (GLA) but reported an improvement in lens comfort in treatment group.
Visual display terminal users
There were two studies observing the effect of supplementation in visual display terminal users (VDTU) both of which found significant improvement. These studies involve a great number of patients aged between 20 and 30 years old (Bhargava et al. 2015a,b) .
Meibomian gland dysfunction
The best objective and subjective results were observed in a study performed in patients suffering Meibomian gland dysfunction (Oleñik et al. 2013 ).
Rheumatoid disease
One study with a small sample size evaluated oral supplementation in patients suffering dry eye associated with rheumatoid disease as lupus or rheumatoid arthritis (Pinheiro et al. 2007 ).
Supplements
The main component of oral supplements is omega-3 fatty acids:
EPA, DHA and a-linolenic acid (ALA). The first two omega-3 fatty acids are found in fish oil; in contrast, ALA is present in some plants. Omega-6 fatty acids included in supplements are gamma-linolenic acid (GLA) and linoleic acid (LA); both are found in vegetable and seeds oils.
With respect to the type of supplement and the total daily dosage of omega-3 and omega-6, there are notable differences between studies (Table 2) .
Eight studies used commercial preparations (they could be acquired by regular purchase), which differ in composition. Two of the supplements had a higher percentage of omega-6 (Larmo et al. 2010; Sheppard et al. 2013 ) than omega-3, and only one used exclusively omega 6 (Kokke et al. 2008) . The remaining studies employed experimental preparations.
Follow-up
The mean follow-up time was 3.9 months (range min-max 1.5-6), and the median was 3 months (P 25 : 3 P 75 : 6).
Dropouts and adverse effects
A total of 166 dropouts were reported. The main cause was gastric intolerance (82) followed by no compliance (59) and others such as cutaneous rash (13).
Use of supplemental therapies
All studies allowed the use of artificial tears, and in some studies, artificial tears were even provided to all the subjects to homogenize their use.
None of the studies allowed active topical medication.
Qualitative/subjective improvement Subjective improvement was assessed in all studies. Six studies used the OSDI, and the DESS is used in four. The five remaining studies used nonstandardized tests: two different visual analogue scales (VAS) and other tests elaborated by examiners.
The four studies that used the DESS and the three of six studies that used the OSDI found statistically significant improvements in DES symptoms. None of the studies using a nonstandardized test found differences between groups (Table 1) .
Quantitative/objective improvement
Tear break-up time (TBUT)
Tear break-up time (TBUT) is assessed in all studies. Pre-and post-treatment values are shown in Fig. 2 , when reported by the authors of the studies. Six studies found differences which were not statistically significant, and nine studies observed a statistically significant improvement (Table 1) .
Schirmer's test
The Schirmer's test is used in all studies but one (Kokke et al. 2008 ). Eight do not use anaesthesia (Schirmer's test type 1) in contrast with four that do (type 2); the remaining study did not specify test type. Statistically significant differences were found in four trials (Fig. 3) .
Quality evaluation
To evaluate the quality of the RCTs, we prioritized those characteristics that claim to minimize the risk of bias (Table 3 ). All the studies had a randomized double-blind parallel design. Information about the sequence of random generation and allocation concealment was only specified in four studies (Kokke et al. 2008; Kangari et al. 2013; Sheppard et al. 2013; Bhargava et al. 2015a,b) .
Discussion
A systematic review of RCTs is presented to assess the efficacy of oral supplementation with omega-3 and/or Test results: (+): significant differences (À): no significant differences. Schirmer's test: (1) type 1; (2) type 2 (?) not specified.
omega-6 fatty acids for DES treatment. The RCT with allocation concealment and double blinding is the most appropriate to assess any intervention in which subject or examiner's expectations could influence data collection. We could assume that all studies meet this requirement; however, it is important to specify it in the study design section.
Dry eye syndrome aetiology
Contact lens wearers
The regular use of contact lens induces ocular surface changes that lead to dry eye symptoms. In vivo confocal microscopy has evidenced morphologic changes in Meibomian glands in contact lens wearers (Villani et al. 2011 ); reduction in goblet cells in impression cytology has also been correlated with contact lens (Sapkota et al. 2016 ). Contact lenses produce significant changes in tear film and cellular metaplasia (Sengor et al. 2012) ; the use of oral supplementation could be beneficial in this group of subjects suffering 'inflammatory dry eye'. The two studies that analyse the effect of supplements in contact lens wearers differ in their Tear break up Ɵme MGD Not specified Not specified Not specified Not specified RD findings. These differences could be explained by the sample size 496 versus 76 subjects or by the use of different supplements as a higher proportion of omega-6 fatty acids has been related to higher dry eye risk (Walter et al. 2016) .
Visual display terminal users
The increased use of visual display terminals has raised the prevalence of associated morbidity such as musculoskeletal and psychopathological symptoms, temporo-mandibular disorders and dry eye. Computer vision syndrome is a group of visual symptoms experienced in relation to the use of computers. Nearly 60 million people suffer from CVS globally, resulting in reduced productivity at work and reduced quality of life of the computer worker (Ranasinghe et al. 2016 ). These problems are being increased with the raise of new technologies and the use of smartphones, tablets and other backlit dispositive.
When reading in an electronic terminal, the blink rate is decreased and the percentage of incomplete blinks rises, which might provoke dry eye symptoms (Argiles et al. 2015) .
Omega-3 supplementation could increase tear stability in these young patients improving eye comfort as they modify intracellular lipids in lacrimal glands (Andrade et al. 2014) . Both studies analysed found dry eye improvement as we could expect.
The difference between studies is the daily dosage; we noticed that higher daily dosage is not associated with larger effects but with increased adverse effects.
VDTU VDTU
Contact lense Menopause MGD Not specified Not specified Not specified Not specified RD 
Meibomian gland dysfunction
Evaporative dry eye is directly related to MGD or posterior blepharitis. These patients experience dry eye discomfort as a result from ocular surface inflammation, which in turn stimulates immune-mediated inflammatory processes, further exacerbating the condition (Macsai 2008) . The use of omega-3 and omega-6 has been related to quality and quantity of intracellular lipids; this fact in combination with a reduced inflammation environment could improve dry eye parameters in these patients (Liu et al. 2016 ).
In the same way, Meibomian gland dysfunction is a frequent dry eye cause with a clear inflammation component that could beneficiate dietary PUFFAs effect.
Rheumatoid disease
There is evidence of improvement in patients suffering dry eye associated with rheumatoid disease (Pinheiro et al. 2007 ). Study is not larger enough to strongly recommend it.
Participant's characteristics
There were notable differences in the characteristics of the participants across the different studies that could explain the disparity in the results when they are considered altogether. First of all, there was remarkable heterogeneity in relation to age. Ocular surface homoeostasis decreases with ageing. Studies performed in a younger population show better baseline objective parameters compared to those with older participants. We could observe that basal TBUT differs between studies with different participant ages: basal TBUT was 11.7 and 9.7 in Bhargava & Kumar (2015) and Bhargava et al. (2015a,b) versus 3.9, 4.7 and 5.9 in Creuzot-Garcher et al. (2011) , Kangari et al. (2013) and Sheppard et al. (2013) . Despite the basal values, the relative improvement seems to be similar between studies.
Regarding gender, there is an unequal distribution with predominance of women. This could be motivated by several different reasons: (1) DES is two times more frequent in women (Malet et al. 2014) . (2) The participants of some studies suffer from Sj€ ogren disease, which is more prevalent in women (Creuzot et al. 2006; Pinheiro et al. 2007) . (3) The studies with the largest sample size among others are limited to women (Sheppard et al. 2013; Bhargava & Kumar 2015; Bhargava et al. 2015a, b) . None of the studies compared the effect of supplementation according to sex.
Supplements characteristics
Daily dosage was heterogeneous, making it difficult to establish a recommended daily intake of omega-3/omega-6 oral supplementation for DES. Efficacy does not seem to correlate with dose increase once a minimum is reached. Significant improvement was observed in studies using 420 mg/ day, while others using 1800mg/day found no effect Kawakita et al. 2013) . Differences are evidenced using omega-3 exclusively or combined with omega-6.
Higher proportion of omega-6 has been related to higher risk of dry eye (Miljanovic et al. 2005) . Those studies using omega-6 in a higher proportion did not find significant differences in objective parameters, even showing deterioration of these parameters (Kokke et al. 2008; Larmo et al. 2010; Sheppard et al. 2013 ).
Dry eye syndrome evaluation and nutritional supplements efficacy Dry eye syndrome (DES) treatment efficacy is difficult to assess as objective and subjective parameters are usually discordant; patients could be experiencing DES symptoms even with normal function examinations and vice versa.
The most used subjective assessment instruments were validated questionnaires used in clinical practice: DESS and OSDI. However, some studies used non-validated instruments. We observed that studies using validated instruments reached findings with significant differences, in contrast to those that use their own instrument. We encourage researchers of future studies to use validated instruments as results are comparable and replicable. Using both DESS and OSDI could be a good approach as each assessed different symptoms.
Objective parameters are an easier method and are supposedly more reliable to measure supplementation effect if they are always done under the same conditions. Data retrieval is also easier because it is a standardized and comparable procedure; even so, results are quite consistent. Tear break-up time (TBUT) was improved in 9 of 15 studies. The best results were achieved in studies performed in contact lenses wearers, computer users and patients affected by Meibomian gland dysfunction (Oleñik et al. 2013; Bhargava & Kumar 2015; Bhargava et al. 2015a,b) . These DES aetiologies are linked to the younger participants, and, as has been previously discussed, this should be taken into account when interpreting the results.
Schirmer's test showed improvement in 4 of 15 studies. As was observed with TBUT, the participants of these studies are younger and the causes of DES are the use of contact lenses, intensive computer use or Sj€ ogren syndrome (Pinheiro et al. 2007; Bhargava et al. 2013 Bhargava et al. , 2015a Bhargava & Kumar 2015) .
Animal models
Studies in animals have evidenced influence of PUFAs in the visual system. Retina and lacrimal glands incorporate dietary fatty acids, indicating that both tissues are very sensitive to dietary changes and fatty acids composition (Schnebelen et al. 2011) . Also, lacrimal measurements in rats after a period of supplementation have shown an increase in tear production and lower ocular surface inflammation (Andrade et al. 2014) . Dietary PUFFAs have been revealed as a protector factor against dry eye signs in experimental rats suffering pilocarpine-induced dry eye. Dietary EPA+DHA could modify anti-inflammatory/pro-inflammatory ratio and decrease pro-inflammatory prostaglandin levels in lacrimal gland. Supplemented animals showed a decrease in clinical signs of corneal chronic dryness (Viau et al. 2009 ).
Limitations
Our systematic review is limited to RCTs, the type of epidemiological design with the highest level of scientific evidence, but comparisons between studies should be made carefully because participants differ in important features related to the main outcomes of interest, such as age or aetiology of DES.
The composition and posology of alimentary supplements differed from one study to another. The aetiology and severity of DES might determine the effects of supplementation.
Future perspectives
More studies are needed to adequately assess the efficacy of omega-3/omega-6 oral supplements. We strongly recommend the use of thorough and validated assessment instruments and the recruitment of a homogeneous sample of participants from a unique aetiology of DES.
Conclusions
The available scientific evidence shows variable results regarding the efficacy of omega-3/omega-6 oral supplementations in DES. According to composition, evidence suggests omega-3 fatty acids should be the main component of oral supplements alone or in combination with a lower proportion of omega-6.
The benefit of oral supplementation is determined by the characteristics of the DES. We have found that the age of the subject and dry eye's aetiology could modify PUFAs effectiveness. Intensive screen device users and contact lens wearers are the population groups that experience the clearer benefits of omega-3/omega-6 supplementation. Oral supplementation took some weeks to achieve eye effect, and it longs while oral caps are used, so it would be beneficial if used as an adjuvant treatment in subjects with chronic dry eye as another instrument in our fight against dry eye.
